Samsung, Qualcomm 2nm Chip Deal Delayed Over Pricing 
Tabletop particle accelerator could transform medicine and materials science 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
Meta’s AI Shopping Push Grows as Agentic Commerce Remains Below 1% 
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota 
Apple Unveils $1,999 Foldable iPhone Duo 
Fitch Eyes Japan Budget for Fiscal Discipline 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Trump Administration Releases New UFO Files and Apollo Mission Records 
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows 
Central Banks Could Buy 20,000 Tonnes of Gold: BofA 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites 
Add as a preferred source on Google
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
